alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 501–525 of 763 studies (page 21 of 31) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 763 studies tagged tau — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Neurofibrillary tangles in Alzheimer's disease and progressive supranuclear palsy: antigenic similarities and differences. Microtubule-associated protein tau antigenicity is prominent in all types of tangles

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Acta neuropathologica 1987-01-01

The antigenic profile of neurofibrillary tangles (NFT) in Alzheimer's disease (AD), senile dementia of Alzheimer type (SDAT), progressive supranuclear palsy (PSP) and in non-demented aged humans was investigated by light and electron microscopic immunocytochemistry using antisera and monoclonal antibodies to tubulin, microtubule-associated proteins (MAP1, MAP2 and tau), neurofilament proteins and determinants unique to Alzheimer paired helical filaments (PHF). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Identification of nuclear tau isoforms in human neuroblastoma cells

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Proceedings of the National Academy of Sciences of the United States of America 1990-11-01

The tau proteins have been reported only in association with microtubules and with ribosomes in situ, in the normal central nervous system. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Biological psychiatry 2004-08-01

Mild cognitive impairment is considered to be a transitional stage between normal aging and dementia. 4 key findings →

Participants: 16 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Molecular genetics and metabolism reports 2023-08-21

Creatine transporter deficiency (CTD) is a rare X-linked disorder of creatine transport caused by pathogenic variants in SLC6A8 (Xq28). 4 key findings →

Participants: 12 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of neurology 2026-04-30

Cognitively impaired patients with negative biomarkers of amyloidosis but with neurochemical evidence of Tau pathophysiology or neurodegeneration or both are classified as "suspected non-Alzheimer pathophysiology" (SNAP), according to the 2018 research framework for a biological definition of Alzheimer's disease (AD). 4 key findings →

Participants: 99 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A novel C. elegans model for MAPT/Tau spreading reveals genes critical for endolysosomal integrity and seeded MAPT/Tau aggregation

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Autophagy 2025-08-25

The spreading of MAPT/Tau pathology is closely associated with the progression of neurodegeneration and cognitive decline in Alzheimer disease and other tauopathies. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Subtracting First Principal Component May Improve 4R Tau Detectability on [ 18 F]Flortaucipir Tau PET

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of Nuclear Medicine 2026-01-22

Area under the receiver operating characteristic curves differentiating PSP and controls were improved by PC1 subtraction in the frontal white matter (0.54 to 0.67; P = 0.002) and subcortical (0.69 to 0.87; P < 0.001) regions. 4 key findings →

Participants: 141 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-12-01

AcTau174 levels were elevated in all dementia groups compared to controls, with a stepwise increase from controls to MCI-AD (2.2-fold) to AD dementia (3.5-fold, Figure 1). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

TDP-43: [GU]-ardian of the transcriptome

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Molecular Neurodegeneration 2026-05-14

TDP-43 is a ubiquitously expressed, primarily nuclear DNA/RNA-binding protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Temporal transcriptomic changes in the THY-Tau22 mouse model of tauopathy display cell type- and sex-specific differences

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Acta Neuropathologica Communications 2025-05-07

We identified several significant sex-specific and sex-dimorphic differentially expressed genes in neurons, microglia, astrocytes and oligodendrocytes, including both cross-sectional changes and alterations from 7 months to 17 months of age. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain organoids in Alzheimer disease and related tauopathies: Challenges and opportunities for translational readiness

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Stem Cell Reports 2026-08-20

A major hurdle in Alzheimer disease research is the failure of mouse models to capture complexities of the human brain that contributes to repeated clinical trial failure. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Acta neuropathologica communications 2022-08-09

Quantification of in vivo amyloid and tau PET imaging relationships with postmortem measurements are critical for validating the sensitivity and specificity imaging biomarkers across clinical phenotypes with Alzheimer disease neuropathologic change (ADNC). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2018-02-01

In vivo 11 C-PBB3 binding to the rTg4510 neocortex/hippocampus was increased relative to controls and correlated with local atrophy. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tau and alpha-synuclein inclusions in a case of familial frontotemporal dementia and progressive aphasia

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of neuropathology and experimental neurology 2005-03-01

Recent studies have shown that neurofibrillary tangles are frequently accompanied by alpha-synuclein inclusions in sporadic and familial Alzheimer disease, in Down syndrome, in progressive supranuclear palsy, and Parkinsonism dementia complex of Guam. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Experimental neurology 2002-10-01

A multitiered strategy was adopted to assess tau conformational changes within fibrillar lesions during the progression of Alzheimer's disease (AD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of biological chemistry 2006-11-03

Intraneuronal accumulation of hyperphosphorylated protein tau in paired helical filaments together with amyloid-beta peptide (Abeta) deposits confirm the clinical diagnosis of Alzheimer disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ANU-ADRI scores, tau pathology, and cognition in non-demented adults: the CABLE study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2024-03-26

It has been reported that the risk of Alzheimer's disease (AD) could be predicted by the Australian National University Alzheimer Disease Risk Index (ANU-ADRI) scores. 4 key findings →

Participants: 476 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neighborhood disadvantage, systemic inflammation, and tau pathology: a link between social determinants of health and Alzheimer's disease risk

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2025-12-01

Higher ADI was significantly associated with increased CRP (r=0.469, p = 0.002) and TREM-1 (r=0.316, p = 0.047). 5 key findings →

Design: cross-sectional Participants: 40 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Tau is associated with atrophy in MCI independently of beta‐amyloid and APOE e4 genotype

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2025-12-01

The first SVD component accounted for 21.56%, 12.93%, 11.91% of the total co-variability between the pairs (cortical thickness, tau), (relative GM density, tau) and (absolute GM density, tau), respectively. 5 key findings →

Design: cross-sectional Participants: 222 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

10 of the 758 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed